{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:33:54Z","timestamp":1793223234987,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004590","name":"Helse Midt-Norge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.atherosclerosis.2026.121903","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:48:18Z","timestamp":1789501698000},"page":"121903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lipoprotein(a) in acute myocardial infarction \u2013 insights from the randomised ASSAIL-MI trial"],"prefix":"10.1016","volume":"422","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4316-805X","authenticated-orcid":false,"given":"Kaspar","family":"Broch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne K.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Anstensrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindre","family":"Woxholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August","family":"Fl\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Bj\u00f8rkelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind H.","family":"Lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir \u00d8.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Wiseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Gullestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.121903_bib1","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102361","article-title":"Limitations of Risk- and symptom-based screening in predicting first myocardial infarction","volume":"4","author":"Mueller","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0735-1097(99)00260-0","article-title":"The relative influence of secondary versus primary prevention using the national cholesterol education program adult treatment panel II guidelines","volume":"34","author":"Goldman","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0735-1097(93)90213-K","article-title":"Myocardial injury: the acute phase response and lipoprotein metabolism","volume":"22","author":"Rosenson","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib5","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1093\/eurheartj\/eht435","article-title":"How to use C-reactive protein in acute coronary care","volume":"34","author":"Biasucci","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib6","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib8","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib11","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib12","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a european atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib13","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2019.07.001","article-title":"Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype","volume":"289","author":"Yahya","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib15","article-title":"Changes in lipoprotein(a) concentrations in patients with acute coronary syndrome","volume":"135","author":"Sata\u0142a","year":"2025","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115531","article-title":"Changes in lipoprotein(a) levels in people after ST elevation myocardial infarction-the STEMI-lipids study","volume":"24","author":"Sourij","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead035","article-title":"Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up","volume":"3","author":"Ziogos","year":"2023","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0021-9150(89)90218-9","article-title":"Transient changes of serum lipoprotein(a) as an acute phase protein","volume":"78","author":"Maeda","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib19","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"M\u00fcller","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2023.09.001","article-title":"Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: is there an association?","volume":"54","author":"Makris","year":"2023","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijcard.2018.06.093","article-title":"Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction","volume":"274","author":"Ueland","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001108","article-title":"Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)","volume":"6","author":"Anstensrud","year":"2019","journal-title":"Open Heart"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of Interleukin-6 receptor inhibition in patients with acute ST-Segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national lipid association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0953-6205(00)00098-4","article-title":"Dynamics of serum interleukin-6 level in patients with acute myocardial infarction","volume":"11","author":"Kucharz","year":"2000","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib28","first-page":"113","article-title":"Association of plasma interleukin-6 with infarct size, reperfusion injury, and adverse remodelling after ST-elevation myocardial infarction","volume":"11","author":"Tiller","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib29","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104013","article-title":"Interleukin-6 inhibition in ST-elevation myocardial infarction: immune cell profile in the randomised ASSAIL-MI trial","volume":"80","author":"Huse","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2023-002301","article-title":"Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab","volume":"10","author":"Woxholt","year":"2023","journal-title":"Open Heart"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib32","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.125.005345","article-title":"Integrative proteomic and lipidomic analysis of patients with acute myocardial infarction treated with PCSK9 antibodies and statins","volume":"19","author":"Schmidt","year":"2026","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/clinchem\/38.4.569","article-title":"Normal variation of plasma lipoproteins: postural effects on plasma concentrations of lipids, lipoproteins, and apolipoproteins","volume":"38","author":"Miller","year":"1992","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2026.121903_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejim.2025.01.021","article-title":"Lipoprotein(a) and prothrombotic effects: evidence from a genetic association study","volume":"135","author":"Olmastroni","year":"2025","journal-title":"Eur J Intern Med"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:03:25Z","timestamp":1793221405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026012694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":36,"alternative-id":["S0021915026012694"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121903","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) in acute myocardial infarction \u2013 insights from the randomised ASSAIL-MI trial","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121903"}}